Adma Biologics (ADMA) Amortization - Intangibles (2017 - 2026)

Adma Biologics (ADMA) has 9 years of Amortization - Intangibles data on file, last reported at $51000.0 in Q4 2025.

• Quarterly Amortization - Intangibles rose 104.0% year-over-year to $51000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146000.0 (down 62.37% YoY) and the FY2025 annual result came in at $144000.0, down 62.89% from the prior year.
• Amortization - Intangibles grew to $51000.0 in Q4 2025, from $38000.0 in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $224000.0 in Q4 2023 to a low of $25000.0 in Q4 2024.
• A 5-year average of $146850.0 and a median of $200000.0 in 2021 frame the typical range for Amortization - Intangibles.
• Annual changes were most pronounced in 2024 — Amortization - Intangibles plunged 88.84% — and 2025, when it soared 104.0%.
• Tracing ADMA's Amortization - Intangibles over 5 years: stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then gained by 12.0% to $224000.0 in 2023, then sank by 88.84% to $25000.0 in 2024, then soared by 104.0% to $51000.0 in 2025.
• The last three Amortization - Intangibles figures came in at $51000.0 (Q4 2025), $38000.0 (Q3 2025), and $32000.0 (Q2 2025), per Business Quant data.